XSHE
000985
Market cap343mUSD
Oct 09, Last price
17.86CNY
1D
0.68%
1Q
23.51%
Jan 2017
-41.82%
IPO
23.43%
Name
Daqing Huake Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Daqing Huake Company Limited, founded in 1998 and headquartered in Daqing, China, operates primarily in the chemical sector within the country. The company specializes in the research, manufacturing, and distribution of petrochemicals and various fine chemical products. Its extensive chemical offerings include heavy and light aromatics, crude compounds such as isopentene, isoprene, and pentadiene, industrial acetonitrile, dicyclopentadiene, ethylene tar, hydrogenated pentene, light-colored petroleum resins, and intermittent liquid-phase bulk polypropylene powder. Beyond chemicals, Daqing Huake also produces a range of plastic items, notably specialized polypropylene materials for woven bag coatings and polyethylene insulation for communication cables, as well as a selection of medical and health-related goods. The company maintains an international presence, exporting its diverse product lines to approximately 20 countries and regions worldwide, including significant markets in Europe, Southeast Asia, and North America.
Key people
Hongtao Wang
Chairman of the Board · since 2023
Yunfeng Wu
Chief Financial Officer · since 2022
Bin Liu
Chief Accounting Officer
Yingshuang Guo
Deputy General Manager, Safety Director · since 2023
Bo Jiang
Deputy General Manager · since 2023
Xiongsen Zhang
Deputy General Manager
Fanli Meng
Secretary of the Board · since 2022
Tao Ben
Director · since 2023
Yan Dou
General Manager, Director · since 2025
Jinbo Geng
Director
Songyan Li
Director · since 2023
Xin Meng
Director · since 2023
Honghai Sun
Director · since 2023
Wei Wang
Director · since 2023
Jincai Yuan
Director · since 2013
Zhijun Zeng
Director · since 2019
Guofeng Li
Independent Director · since 2023
Ming Pan
Independent Director · since 2023
Yingchao Teng
Independent Director
Independent Director · since 2020
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑00 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||